These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30312726)

  • 61. A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel.
    França F; Silva PMA; Soares JX; Henriques AC; Loureiro DRP; Azevedo CMG; Afonso CMM; Bousbaa H
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33322077
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tank Binding Kinase 1 modulates spindle assembly checkpoint components to regulate mitosis in breast and lung cancer cells.
    Maan M; Agrawal NJ; Padmanabhan J; Leitzinger CC; Rivera-Rivera Y; Saavedra HI; Chellappan SP
    Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118929. PubMed ID: 33310066
    [TBL] [Abstract][Full Text] [Related]  

  • 63. KIAA0101 and UbcH10 interact to regulate non-small cell lung cancer cell proliferation by disrupting the function of the spindle assembly checkpoint.
    Lei H; Wang K; Jiang T; Lu J; Dong X; Wang F; Li Q; Zhao L
    BMC Cancer; 2020 Oct; 20(1):957. PubMed ID: 33008389
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer.
    Ganapathi RN; Norris EJ; Sutker AP; Klotz KE; Ganapathi MK
    Front Oncol; 2020; 10():1354. PubMed ID: 32974133
    [TBL] [Abstract][Full Text] [Related]  

  • 65. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit.
    Chae HD; Dutta R; Tiu B; Hoff FW; Accordi B; Serafin V; Youn M; Huang M; Sumarsono N; Davis KL; Lacayo NJ; Pigazzi M; Horton TM; Kornblau SM; Sakamoto KM
    Oncotarget; 2020 Jun; 11(25):2387-2403. PubMed ID: 32637030
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.
    Guo S; Zhang J; Wei C; Lu Z; Cai R; Pan D; Zhang H; Liang B; Zhang Z
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1097-1108. PubMed ID: 32449143
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Centrosomal and Non-centrosomal Functions Emerged through Eliminating Centrosomes.
    Takeda Y; Kuroki K; Chinen T; Kitagawa D
    Cell Struct Funct; 2020 May; 45(1):57-64. PubMed ID: 32269206
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regulation of Mitotic Exit by Cell Cycle Checkpoints: Lessons From
    Matellán L; Monje-Casas F
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32059558
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity.
    Yin L; Zeng Y; Xiao Y; Chen Y; Shen H; Dong J
    Cell Death Dis; 2019 May; 10(6):385. PubMed ID: 31097686
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Target driven preclinical screening for new antimitotic chemotherapy agents.
    Novío S; Freire-Garabal M; Núñez MJ
    Curr Top Med Chem; 2014; 14(20):2263-71. PubMed ID: 25434356
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
    Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
    Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.
    Huang HC; Shi J; Orth JD; Mitchison TJ
    Cancer Cell; 2009 Oct; 16(4):347-58. PubMed ID: 19800579
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Second-Generation Antimitotics in Cancer Clinical Trials.
    Novais P; Silva PMA; Amorim I; Bousbaa H
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371703
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.
    Schmidt M; Bastians H
    Drug Resist Updat; 2007; 10(4-5):162-81. PubMed ID: 17669681
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
    Giovinazzi S; Bellapu D; Morozov VM; Ishov AM
    Cell Cycle; 2013 Aug; 12(16):2598-607. PubMed ID: 23907120
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.